« Back

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

11/04/14 7:00 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2014-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November. Chris Garabedian, Sarepta’s president and chief executive officer, will be the presenter.

  • 2014 23rd Annual Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014, at 4:00 p.m. MST.
  • Stifel Healthcare Conference 2014 in New York, NY on Wednesday, November 19, 2014, at 10:20 a.m. EST.

The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following each presentation for 90 days.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

Source: Sarepta Therapeutics, Inc.

Sarepta Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Sarepta Media Contact:
Tony Plohoros, 908-940-0135
tplohoros@6degreesPR.com

 

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.